Literature DB >> 16802166

Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.

Stephanie Bomsien1, Rolf Aderjan, Rainer Mattern, Gisela Skopp.   

Abstract

OBJECTIVE: The aim of the present study was to estimate the drug interaction potential of psychtropic medication on buprenorphine (BUP) N-dealkylation using cDNA-expressed cytochrome P450 (CYP) enzymes.
METHODS: BUP was incubated with psychotropic drugs and cDNA-expressed CYP 3A4 and CYP 2C8 enzymes. Seven substances were screened for their inhibition potency. To check for a mechanism-based component in inhibition, all substances were tested with and without preincubation, respectively. Norbuprenorphine (NBUP) concentrations were determined by liquid chromatography/tandem mass spectrometry, following liquid/liquid extraction.
RESULTS: Midazolam and zolpidem demonstrated greatest inhibition in screening experiments. As expected, IC(50) values without preincubation were higher than those after 30-min preincubation, with zolpidem 113.1 microM and midazolam 20.25 microM. Following a 30-min preincubation period in the absence of the probe substrate BUP, the apparent IC(50) values for zolpidem and midazolam were 20.17 microM and 3.5 microM.
CONCLUSION: Both midazolam and zolpidem showed a distinct inhibitory potency towards NBUP formation by CYP 3A4, implicating a decreased conversion of BUP. When preincubated, the inhibitory potency was increased, which strongly suggests a metabolically activated component in inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16802166     DOI: 10.1007/s00228-006-0147-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

2.  Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry.

Authors:  Dominik Grimm; Eva Pauly; Johannes Pöschl; Otwin Linderkamp; Gisela Skopp
Journal:  Ther Drug Monit       Date:  2005-08       Impact factor: 3.681

3.  Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes.

Authors:  Yan Chang; David E Moody
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

4.  Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.

Authors:  L L von Moltke; D J Greenblatt; S X Duan; J Schmider; L Kudchadker; S M Fogelman; J S Harmatz; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

5.  In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

Authors:  Nicolas Picard; Thierry Cresteil; Nassim Djebli; Pierre Marquet
Journal:  Drug Metab Dispos       Date:  2005-03-02       Impact factor: 3.922

6.  A new series of 13 buprenorphine-related deaths.

Authors:  Pascal Kintz
Journal:  Clin Biochem       Date:  2002-10       Impact factor: 3.281

7.  Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.

Authors:  Wenjiang Zhang; Yamini Ramamoorthy; Rachel F Tyndale; Edward M Sellers
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

8.  Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.

Authors:  M Ohtani; H Kotaki; Y Sawada; T Iga
Journal:  J Pharmacol Exp Ther       Date:  1995-02       Impact factor: 4.030

9.  A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.

Authors:  David E Moody; Matthew H Slawson; Eric C Strain; John D Laycock; Alan C Spanbauer; Rodger L Foltz
Journal:  Anal Biochem       Date:  2002-07-01       Impact factor: 3.365

10.  Serious overdoses involving buprenorphine in Helsinki.

Authors:  J Boyd; T Randell; H Luurila; M Kuisma
Journal:  Acta Anaesthesiol Scand       Date:  2003-09       Impact factor: 2.105

View more
  2 in total

1.  An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation.

Authors:  Stephanie Oechsler; Gisela Skopp
Journal:  Int J Legal Med       Date:  2010-01-29       Impact factor: 2.686

2.  Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone.

Authors:  Susanne Löfgren; R Michael Baldwin; Margareta Carlerös; Ylva Terelius; Ronny Fransson-Steen; Jessica Mwinyi; David J Waxman; Magnus Ingelman-Sundberg
Journal:  Drug Metab Dispos       Date:  2009-04-01       Impact factor: 3.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.